← Back to Clinical Trials
Recruiting NCT06160635

NCT06160635 D-SOLVE Cohorts (Cohort a and B)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06160635
Status Recruiting
Phase
Sponsor Hannover Medical School
Condition HDV
Study Type OBSERVATIONAL
Enrollment 750 participants
Start Date 2023-02-22
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 750 participants in total. It began in 2023-02-22 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV). This multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.

Eligibility Criteria

Inclusion Criteria: * Anti-HDV positive * ≥18 years old * Sex: m/f/d * Informed consent for prospective procedures Exclusion Criteria: * Anti-HDV negative

Contact & Investigator

Central Contact

Petra Dörge

✉ doerge.petra@mh-hannover.de

📞 +495115326057

Principal Investigator

Markus Cornberg

PRINCIPAL INVESTIGATOR

Hannover Medical School

Frequently Asked Questions

Who can join the NCT06160635 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying HDV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06160635 currently recruiting?

Yes, NCT06160635 is actively recruiting participants. Contact the research team at doerge.petra@mh-hannover.de for enrollment information.

Where is the NCT06160635 trial being conducted?

This trial is being conducted at Hanover, Germany, Milan, Italy, Bucharest, Romania, Stockholm, Sweden.

Who is sponsoring the NCT06160635 clinical trial?

NCT06160635 is sponsored by Hannover Medical School. The principal investigator is Markus Cornberg at Hannover Medical School. The trial plans to enroll 750 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology